Publications by authors named "Sara R Metzler"
Clin Cancer Res
October 2019
Article Synopsis
- Bendamustine and rituximab (BR) has proven to be a more effective first-line treatment for follicular lymphoma (FL) compared to the traditional R-CHOP regimen, and the study evaluated the efficacy of adding yttrium-90 Ibritumomab tiuxetan (YIT) as a consolidation strategy.
- The trial included 39 untreated FL patients aged 18 and older, who underwent initial rituximab therapy followed by four cycles of BR, and then potentially received YIT as consolidation if they showed at least a partial response.
- Results showed a high overall response rate of 94.8%, with 77% achieving a complete response, and a progression-free survival rate of
